Loading...
01/09 21:01
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial metrics, including a 25.2% increase in adjusted EBITDA and a 12.4% rise in margins, with a robust cash position and no debt. Despite some vague responses in the Q&A, the raised guidance for 2024 and strategic market expansion are positive indicators. The small-cap nature of the company suggests a more pronounced market reaction, likely resulting in a stock price increase of 2% to 8%.
Implemented Providers 4,789 implemented providers, an increase of 11.2% year-over-year.
Practice Collections $792.5 million, an increase of 4.7% year-over-year; excluding renegotiated Medicare Advantage agreements, it increased approximately 12.4%.
Adjusted EBITDA $24.9 million, up 44% year-over-year, representing 23.1% of care margin, a 420 basis point improvement.
Total Practice Collections (Full Year) $2.97 billion, an increase of 4.5% year-over-year.
Care Margin (Full Year) Up 12.4% year-over-year.
Adjusted EBITDA (Full Year) $90.5 million, up 25.2% year-over-year.
Free Cash Flow $109.3 million, converting 121% of adjusted EBITDA, higher than previous guidance due to timing of cash payments and prudent working capital management.
Cash Position $491 million in cash and no debt at year-end.
Implemented Providers Growth: Implemented providers increased 11.2% year-over-year, reaching 4,789 providers.
Attributed Lives Growth: Total attributed lives increased more than 11% from a year ago, reaching over 1.26 million attributed lives.
Commercial Attributed Lives Growth: Commercial attributed lives increased 15.2% from last year to reach 782,000.
Medicare Advantage and Medicaid Attribution Growth: Medicare Advantage and Medicaid attribution both increased almost 8% from a year ago.
Free Cash Flow: Privia generated a record $109.3 million in free cash flow in 2024, converting 121% of adjusted EBITDA.
Adjusted EBITDA Growth: Adjusted EBITDA was up 25.2%, reaching $90.5 million.
Care Margin Growth: Care margin was up 12.4% year-over-year.
Operating Margin Expansion: Operating leverage drove margin expansion of 230 basis points year-over-year.
2025 Guidance: For 2025, implemented providers are expected to increase 9.6% year-over-year to reach 5,250.
Focus Areas for 2025: Core priorities include provider growth, attribution growth, and operational improvements.
Capital Expenditures: Capital expenditures are expected to be de minimis again this year as part of a capital-light operating model.
Medicare Advantage Environment: Privia expects headwinds in Medicare Advantage over the next few years due to elevated utilization trends, phase-in of V28 through 2026, and changes in Star Scores.
Regulatory Challenges: The company acknowledges risks and uncertainties related to future financial and operating performance, which are influenced by the current healthcare and regulatory environment.
Market Competition: Privia's growth strategy is focused on disciplined growth in existing markets, indicating awareness of competitive pressures in the healthcare sector.
Operational Efficiency: The company aims to manage risk and implement clinical and operational enhancements, highlighting the challenges in maintaining operational efficiency.
Tax Liabilities: Privia anticipates an increase in cash taxes in 2025 due to nearing the end of their net operating loss carryforward, which may impact cash flow.
Implemented Providers Growth: Implemented providers increased 11.2% year-over-year, reaching 4,789 providers.
Free Cash Flow: Privia generated a record $109.3 million in free cash flow in 2024, converting 121% of adjusted EBITDA.
Provider Retention: Gross provider retention of 98% highlights the stickiness of the model.
Attributed Lives: Privia serves over 1.26 million attributed lives across commercial and government value-based care programs.
Expansion Plans: Privia aims to build one of the largest primary care-centric delivery networks in the nation.
2025 Implemented Providers Guidance: Expected to increase 9.6% year-over-year to reach 5,250 by year-end.
2025 Attributed Lives Growth: Expected growth of approximately 7.5%.
2025 Practice Collections Growth: Expected growth of approximately 7.8% at the midpoint.
2025 Adjusted EBITDA Growth: Expected growth of approximately 19% at the midpoint.
2025 EBITDA Margin Expansion: Expected to expand approximately 200 basis points year-over-year.
2025 Capital Expenditures: Expected to be de minimis again this year.
Effective Tax Rate: Assuming an effective tax rate of 26% to 28%.
Free Cash Flow Conversion: Expecting at least 80% of full year adjusted EBITDA to convert to free cash flow.
Free Cash Flow: Privia generated a record $109.3 million in free cash flow in 2024, converting 121% of adjusted EBITDA.
Cash Position: Privia ended the year with $491 million in cash and no debt.
2025 Guidance for Free Cash Flow: Privia expects at least 80% of its full year adjusted EBITDA to convert to free cash flow in 2025.
The earnings call highlights strong financial performance, optimistic guidance for 2025, and strategic growth in new markets. The Q&A section revealed positive analyst sentiment, with questions focusing on growth opportunities and market expansion. Despite some cautious language from management, the overall tone was positive. The company's strategic plan and guidance raise are expected to positively impact the stock price, especially given the small-cap nature of the company. The positive sentiment and strategic growth initiatives outweigh any concerns about cautious language or limited Q4 profitability growth.
The earnings call summary and Q&A highlight strong financial performance, strategic growth, and optimistic guidance. Key positive factors include broad-based growth, effective risk management, and favorable regulatory impacts. The IMS integration is progressing well, and the company is raising its 2025 revenue outlook. Despite increased G&A expenses, the company's balanced model and platform enhancements provide significant opportunities. The market cap indicates a moderate reaction, leading to a 'Positive' prediction for stock price movement in the next two weeks.
The earnings call reveals strong financial performance with a 12.8% increase in total practice collections and a 35.1% rise in adjusted EBITDA. The Arizona acquisition is expected to be EBITDA positive, and the 2025 guidance has been raised. Despite challenges in the Medicare Advantage market and competitive pressures, the company shows solid growth and financial health. The Q&A section highlights management's confidence in future utilization trends and organic growth. Given the company's market cap, the stock price is likely to react positively, potentially in the 2% to 8% range.
The earnings call highlights strong financial metrics, including a 25.2% increase in adjusted EBITDA and a 12.4% rise in margins, with a robust cash position and no debt. Despite some vague responses in the Q&A, the raised guidance for 2024 and strategic market expansion are positive indicators. The small-cap nature of the company suggests a more pronounced market reaction, likely resulting in a stock price increase of 2% to 8%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
